Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2004 3
2006 1
2007 1
2011 1
2012 1
2016 2
2017 4
2018 5
2019 1
2020 1
2021 1
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report.
Sagawa T, Sato Y, Nagashima H, Takada K, Takahashi M, Hirakawa M, Hamaguchi K, Tamura F, Fujikawa K, Okamoto K, Kawano Y, Sogabe M, Miyamoto H, Takayama T. Sagawa T, et al. Among authors: fujikawa k. Front Immunol. 2023 Jul 10;14:1203621. doi: 10.3389/fimmu.2023.1203621. eCollection 2023. Front Immunol. 2023. PMID: 37492584 Free PMC article.
Identifying Early Predictive Markers for Immune-Related Adverse Events in Nivolumab-Treated Patients with Renal Cell Carcinoma and Gastric Cancer.
Takada S, Murooka H, Tahatsu K, Yanase M, Umehara K, Hashishita H, Toru H, Satoru M, Sagawa T, Fujikawa K, Sato H, Mino K. Takada S, et al. Among authors: fujikawa k. Asian Pac J Cancer Prev. 2022 Feb 1;23(2):695-701. doi: 10.31557/APJCP.2022.23.2.695. Asian Pac J Cancer Prev. 2022. PMID: 35225483 Free PMC article.
Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma.
Fujiwara Y, Takahashi Y, Okada M, Kishimoto T, Kondo S, Fujikawa K, Hayama M, Sugeno M, Ueda S, Komuro K, Lanasa M, Nakano T. Fujiwara Y, et al. Among authors: fujikawa k. Oncologist. 2022 Sep 2;27(9):e703-e722. doi: 10.1093/oncolo/oyac099. Oncologist. 2022. PMID: 35671201 Free PMC article. Clinical Trial.
Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study.
Ohnuma H, Sato Y, Hayasaka N, Matsuno T, Fujita C, Sato M, Osuga T, Hirakawa M, Miyanishi K, Sagawa T, Fujikawa K, Ohi M, Okagawa Y, Tsuji Y, Hirayama M, Ito T, Nobuoka T, Takemasa I, Kobune M, Kato J. Ohnuma H, et al. Among authors: fujikawa k. Cancer Sci. 2018 Nov;109(11):3554-3563. doi: 10.1111/cas.13772. Epub 2018 Sep 25. Cancer Sci. 2018. PMID: 30137686 Free PMC article. Clinical Trial.
Case Report: Longitudinal monitoring of clonal evolution by circulating tumor DNA for resistance to anti-EGFR antibody in a case of metastatic colorectal cancer.
Sagawa T, Sato Y, Hirakawa M, Hamaguchi K, Tamura F, Nagashima H, Fujikawa K, Okamoto K, Kawano Y, Sogabe M, Miyamoto H, Takayama T. Sagawa T, et al. Among authors: fujikawa k. Front Oncol. 2023 Jun 26;13:1203296. doi: 10.3389/fonc.2023.1203296. eCollection 2023. Front Oncol. 2023. PMID: 37434969 Free PMC article.
Erratum to: Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study.
Sato Y, Ohnuma H, Nobuoka T, Hirakawa M, Sagawa T, Fujikawa K, Takahashi Y, Shinya M, Katsuki S, Takahashi M, Maeda M, Okagawa Y, Naoki U, Kikuch S, Okamoto K, Miyamoto H, Shimada M, Takemasa I, Kato J, Takayama T. Sato Y, et al. Among authors: fujikawa k. Gastric Cancer. 2017 May;20(3):527. doi: 10.1007/s10120-016-0643-z. Gastric Cancer. 2017. PMID: 27629880 No abstract available.
Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours.
Yonemori K, Tamura K, Kodaira M, Fujikawa K, Sagawa T, Esaki T, Shirakawa T, Hirai F, Yokoi Y, Kawata T, Hatano B, Takahashi Y. Yonemori K, et al. Among authors: fujikawa k. Cancer Chemother Pharmacol. 2016 Sep;78(3):525-31. doi: 10.1007/s00280-016-3106-7. Epub 2016 Jul 15. Cancer Chemother Pharmacol. 2016. PMID: 27422301 Free PMC article. Clinical Trial.
Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab.
Sagawa T, Sato Y, Hirakawa M, Hamaguchi K, Fukuya A, Okamoto K, Miyamoto H, Muguruma N, Fujikawa K, Takahashi Y, Takayama T. Sagawa T, et al. Among authors: fujikawa k. Sci Rep. 2020 Nov 13;10(1):19815. doi: 10.1038/s41598-020-76756-1. Sci Rep. 2020. PMID: 33188279 Free PMC article.
25 results